Category

Lundbeckfonden Ventures
Lund, Sweden, 08.00 CET, 19 November 2018 – BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone voids, today announces positive top-line data from the CERTiFy (CERAMENT® Treatment of Tibia Plateau Fracture defects) study comparing CERAMENT|BVF with autologous iliac bone graft (autograft). BONESUPPORT CEO Emil Billback said:” Successfully completing the ground-breaking CERTiFy study, to demonstrate...
SAN DIEGO – November 13, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the first patient has been dosed in the Company’s Phase 2 clinical program to evaluate the efficacy and safety of APX001 in the treatment of infections caused by Candida. “Initiating our Phase 2 program for...
Cambridge, UK and Indianapolis, US – 6 November 2018: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that it has resubmitted its New Drug Application (NDA) for BARHEMSYS(TM) (amisulpride injection) to the US Food and Drug Administration (FDA). On 8 October, the...
Lund, Sverige, 08.00 CET, 7 november 2018 – BONESUPPORT™, ett ledande företag verksamt inom ortobiologi för behandling av hålrum i ben, avger sin delårsrapport för tredje kvartalet 2018. Framgångsrik etablering av ny distributionsstruktur i USA 1 JULI – 30 SEPTEMBER 2018 Nettoomsättningen uppgick till 14,2 MSEK (32,7), en minskning med 56%. Till följd av vår uppsägning i...
Lund, Sweden, 08.00 CET, 1 November 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids will publish its Q3 2018 Interim Report on Wednesday 7 November 2018 at 8am CET. The Company will hold a conference call and an online presentation on the same day at 10am CET. The call...
Multiple Doses of AU-011 are Well-Tolerated, with Vision Preservation Observed at 12 to 18 Months All Patients Met Preliminary Efficacy Endpoint to Date with Evidence of Biological Activity CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that updated clinical data from its Phase 1b/2...
23RD OCTOBER 2018 EB8018, the lead investigational candidate, targets Crohn’s disease with potential for other GI disorders Paris, France and Cambridge, MA, USA – October 23, 2018 ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion...
Palma, Spain and San Diego, USA, 23 October, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical...
25 independent distributors contracted Total of 512 distributor reps now selling CERAMENT BVF New distribution network will positively impact North American reported sales and net margins   Lund, Sweden, 08:00 CET, 22 October 2018 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, announces that it has started selling CERAMENT® BVF...
Cambridge, UK and Indianapolis, US – 15 October 2018: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”) provides an update following receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) in respect of its New Drug Application (NDA) for BARHEMSYS(TM) (amisulpride injection) on 5 October 2018. “Our discussions...
1 2 3 42

News

New analytical method exposes the body’s policemen
19. November 2018
The world’s only cubed poop can now be scientifically explained
19. November 2018
Genetic sprint – all the way down through the Americas
9. November 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge